Login to Your Account

In the clinic

Wednesday, April 26, 2017

Asterias Biotherapeutics Inc., of Fremont, Calif., said the data monitoring committee recommended continuation of enrollment in the SciStar phase I/IIa trial testing AST-OPC1 for acute spinal cord injury (SCI), with the 10 million and 20 million cell dose cohorts to continue as planned, following an interim review.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription